This case was initiated by CoreValve in the UK in September 2007. In response, Edwards counter-sued, claiming infringement of the patent. While the court upheld Edwards’s patent, it
Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in
The respiratory syncytial virus (RSV)-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus infection in adult
Elevate anterior prolapse repair system is a minimally invasive, single-incision total transvaginal approach for treating cystoceles and vault prolapse. It utilizes minimal blind needle passages and follows proven
The Phase III study is a US multi-center, randomized, controlled trial, in which the efficacy and safety of Trinam will be investigated in patients with end-stage renal disease
To date, the FDA has not approved any product for treating corneal graft rejection. Currently, EyeGate is enrolling two Phase II clinical studies utilizing EGP-437 in uveitis and
Liquidity and Capital Resources As of November 30, 2008, the company working capital deficit of $531,257 was comprised of current assets of $16,073 and current liabilities of $547,330.
Galapagos will be responsible for the discovery and preclinical development of new small molecule candidate drugs based on novel Galapagos targets. Merck will have the exclusive option to
“Our rapid product development capability is an important strategic advantage for Mindray, as it continues to generate new revenue streams in an increasingly price-competitive medical device market,” remarked
“But I like the idea of the American people’s representatives expressing their views on an issue like this,” he said, lauding a “bipartisan” consensus in Congress that such
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.